newsfilter
← Latest News
General Catalyst·

The Case for Accelerating Clinical Drug Trials in the United States ‍

Summary

  • Maryam Mujica serves as President of General Catalyst Institute & Kent Thoelke is Founder & CEO of Paradigm Health, a General Catalyst portfolio company.
  • The U.S. risks losing its global biomedical leadership due to an old, slow, fragmented, & administratively burdensome clinical research infrastructure.
  • Competitors like China, Australia, & India have expanded trial capacity, with China specifically creating faster, cheaper systems backed by regulatory changes.
  • Clinical trials in the U.S. face excessive delays & costs, estimated at $40,000 daily in direct costs & $500,000 in lost prescription sales per day.
  • The cost per novel drug has risen from under $1B in the 1990s to $3.5B today due to site recruitment struggles, administrative burnout, & fragmented data.
  • China tripled R&D spending between 2014 & 2024, resulting in Phase 3 trial costs of $25,000 per patient compared to $69,000 in the U.S.
  • Chinese patient recruitment in late-stage trials is 2 to 5 times faster than in U.S. trials due to large public hospital systems & centralized referral networks.
  • Trial sponsors must make trials more practical by leveraging EHR-embedded technology to streamline data collection & enrollment, as demonstrated in a Johnson & Johnson pilot.
  • The industry must adopt Real-Time Clinical Trials to analyze data during the process rather than post-trial, with Paradigm Health collaborating with the FDA since early 2026 to define standards.
  • Proof of concept trials with Amgen & AstraZeneca aim to establish a blueprint for real-time data interoperability & regulatory validation.
  • Health systems should adopt AI-enabled solutions to connect disparate databases, automate tasks, & reduce researcher burnout, as seen in Ochsner Health's 41% research reach expansion.
  • Trial sponsors must broaden study site distribution beyond academic centers to include community & rural sites like Highlands Oncology Group & Florida Cancer Specialists & Research Institute.
  • Expanding to community sites aims to yield more representative evidence, faster enrollment, & ensure clinical research remains a care option for all Americans.
  • The countries that fastest build efficient, connected, patient-centered clinical research systems will shape the future of global healthcare & possess the healthiest populations.